ResearcherSeoul National UniversityNo recent work listed

Jinwoo Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6510-4850; OpenAlex author ID A5045028984. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2020: 1 paper

Papers 1

Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2020.05.005 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Woo Hyun Paik · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗
Dong‐Won Ahn · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗
Sang Hyub Lee · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗
Jin Ho Choi · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗
Ji Kon Ryu · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗
Yong‐Tae Kim · 1 shared paper, 2020 · strength 0.12
- Paper Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancr… DOI 10.1016/j.hbpd.2020.05.005 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.